What the Evidence Says About Psychedelic-Assisted Therapy for Addiction in 2026
Ibogaine, psilocybin, MDMA, ketamine — the clinical trial landscape is broader than the headlines suggest, but so are the caveats.
Body: [Balanced evidence review: psilocybin for AUD (Johns Hopkins, NYU), ibogaine for OUD (Stanford, Kentucky’s state-funded research), MDMA (field setback after 2024 FDA rejection, what changed), ketamine (already approved for depression, off-label for AUD), what the meta-analyses actually show, safety concerns, regulatory pathway. Concludes with: “promising but not yet ready for routine care.” 900 words.]
Sources Cited
- 01.Ahttps://heal.nih.govNIH HEAL
- 02.Ahttps://clinicaltrials.govClinicalTrials.gov
Filed Under
Peer-Reviewed ResearchMAT — BuprenorphineFederal
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Twelve Veterans Had Already Failed Every PTSD Treatment. Nine Are in Remission After Two Doses of Psilocybin.
A 12-person Ohio State pilot found 75% PTSD remission in veterans after two psilocybin doses. Here's what the number means, what it doesn't prove yet, and how it fits alongside Texas's $50M ibogaine bet and new research on peer support workers.
Science & MedicineThe Ozempic-for-Drinking Trial Just Published Real Numbers. The Headline Effect Missed Its Own Primary Target.
A Phase 2 trial of oral semaglutide for alcohol use disorder found real reductions in heavy drinking days and craving — but missed its own pre-registered primary endpoint. Here's what that gap means, and why the VA is running the next version now.
Science & Medicine45 Million Americans Have a Substance Use Disorder Right Now. The Government's Own Survey Says So — and Says Most Won't Get Treated.
SAMHSA's 2025 NSDUH shows 45 million Americans met SUD criteria in the past year — 15.3% of everyone 12 and older. Here's what the numbers actually say.